PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Teams with UniQuest to Develop Novel Cannabinoid Delivery System
Global nasal drug delivery technology market expected to reach $64 billion by 2021 Development of CBD-infused soluble gel for nasal delivery targets range of diseases Clinical benefits of Sol-gel delivery method include a safer, more reliable delivery platform with higher efficacy Health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) and UniQuest Pty Limited, the main commercialization company of the University of Queensland (UQ), Australia, are expecting 2018 to be an exciting, productive year for joint medical research projects. PreveCeutical Medical, headquartered in Vancouver, British Columbia, has entered into a research and option agreement with the University and…
